Arthneeti
Latest: Windlas Biotech Ltd Q1 FY27 results →All Q1 FY26 results →
WB

Windlas Biotech Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Windlas Biotech Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Price₹994
Market cap₹2.0K Cr
P/E29.5
Updated23 Aug 2026
Read3 min read

Revenue & Sales Performance

  • Commitment is towards long-term growth by leveraging every opportunity and unlocking avenues across all verticals (CDMO, Trade Generics, Exports).
  • Past performance indicates strong growth; e.g., ~50% growth over last 2 financial years.
  • Market dynamics and industry trends suggest room for continuing growth, supported by factors like:
  • Increasing quality and compliance pressures benefiting organized players.
  • Growth in trade generics (often undocumented in industry numbers).
  • Investments in capacity expansion, including Plant 6 and injectables facility.
  • Management emphasizes sustained efforts, operational efficiency, and strategic capacity additions rather than promising fixed growth percentages.

2 more points from Windlas Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Windlas Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Plant 6 refurbishment and validation is ongoing, with 2-3 more quarters expected before full commercialization; CapEx planned is INR 40-50 crores.
  • After Plant 6 reaches full capacity, Windlas Biotech aims to expand into another dosage form if no inorganic opportunities arise.
  • Injectable facility expansion (Plant 5 Phase II) will be considered once peak utilization is achieved; such expansion can be done within 1-2 quarters as utilities are built-in.
  • Organic CapEx will be used judiciously alongside inorganic opportunities for strategic growth.

2 more points from Windlas Biotech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Windlas Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company regards order book size and client-wise order details as competitively sensitive information.
  • Management focuses more on broad-based business development and maintaining a diversified customer base rather than highlighting individual order values.
  • There is an emphasis on sustained growth across verticals driven by volume and new client additions, but exact order backlog data is not shared publicly.

Windlas Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹238 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Windlas Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • RPG LifeScience. (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharma. (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories Ltd (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem Ltd (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Windlas Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What is Windlas Biotech Ltd share price analysis?

Windlas Biotech Ltd currently shows a neutral. The stock trades at a P/E of 29.5 with a market cap of ₹1,959 Cr. Investors should review the full earnings analysis for detailed insights.

Is Windlas Biotech Ltd planning capital expenditure?

Plant 6 refurbishment and validation is ongoing, with 2-3 more quarters expected before full commercialization; CapEx planned is INR 40-50 crores.

Keep Windlas Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.